JP2020514345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514345A5 JP2020514345A5 JP2019549449A JP2019549449A JP2020514345A5 JP 2020514345 A5 JP2020514345 A5 JP 2020514345A5 JP 2019549449 A JP2019549449 A JP 2019549449A JP 2019549449 A JP2019549449 A JP 2019549449A JP 2020514345 A5 JP2020514345 A5 JP 2020514345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- sdf
- fpkm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 15
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 201000007270 liver cancer Diseases 0.000 claims 6
- 208000014018 liver neoplasm Diseases 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 5
- 206010038038 rectal cancer Diseases 0.000 claims 5
- 201000001275 rectum cancer Diseases 0.000 claims 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims 5
- -1 Propane-2-yl Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1703907.4 | 2017-03-10 | ||
| GBGB1703907.4A GB201703907D0 (en) | 2017-03-10 | 2017-03-10 | Novel therapies for cancer |
| PCT/GB2018/050608 WO2018162924A1 (en) | 2017-03-10 | 2018-03-09 | Usl-311 for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514345A JP2020514345A (ja) | 2020-05-21 |
| JP2020514345A5 true JP2020514345A5 (enExample) | 2021-04-22 |
Family
ID=58605592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549449A Pending JP2020514345A (ja) | 2017-03-10 | 2018-03-09 | 新規な癌の治療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200281937A1 (enExample) |
| EP (1) | EP3592356A1 (enExample) |
| JP (1) | JP2020514345A (enExample) |
| KR (1) | KR20190128660A (enExample) |
| CN (1) | CN110520130A (enExample) |
| AU (1) | AU2018231664A1 (enExample) |
| BR (1) | BR112019018482A2 (enExample) |
| CA (1) | CA3055470A1 (enExample) |
| EA (1) | EA201992130A1 (enExample) |
| GB (1) | GB201703907D0 (enExample) |
| IL (1) | IL269121A (enExample) |
| MX (1) | MX2019010679A (enExample) |
| SG (1) | SG11201908166UA (enExample) |
| WO (1) | WO2018162924A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| JP6927882B2 (ja) | 2015-04-02 | 2021-09-01 | プロキシマジェン，リミティド ライアビリティ カンパニー | 癌の新治療法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| JP6927882B2 (ja) * | 2015-04-02 | 2021-09-01 | プロキシマジェン，リミティド ライアビリティ カンパニー | 癌の新治療法 |
| GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
-
2017
- 2017-03-10 GB GBGB1703907.4A patent/GB201703907D0/en not_active Ceased
-
2018
- 2018-03-09 BR BR112019018482A patent/BR112019018482A2/pt not_active Application Discontinuation
- 2018-03-09 AU AU2018231664A patent/AU2018231664A1/en not_active Abandoned
- 2018-03-09 WO PCT/GB2018/050608 patent/WO2018162924A1/en not_active Ceased
- 2018-03-09 SG SG11201908166U patent/SG11201908166UA/en unknown
- 2018-03-09 JP JP2019549449A patent/JP2020514345A/ja active Pending
- 2018-03-09 KR KR1020197028679A patent/KR20190128660A/ko not_active Ceased
- 2018-03-09 EP EP18711658.7A patent/EP3592356A1/en not_active Withdrawn
- 2018-03-09 MX MX2019010679A patent/MX2019010679A/es unknown
- 2018-03-09 EA EA201992130A patent/EA201992130A1/ru unknown
- 2018-03-09 CA CA3055470A patent/CA3055470A1/en not_active Abandoned
- 2018-03-09 CN CN201880024349.5A patent/CN110520130A/zh active Pending
- 2018-03-09 US US16/492,305 patent/US20200281937A1/en not_active Abandoned
-
2019
- 2019-09-04 IL IL26912119A patent/IL269121A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533366A5 (enExample) | ||
| JP2020502157A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| Li et al. | Locally ablative therapies for primary and metastatic liver cancer | |
| JP2014525454A5 (enExample) | ||
| JP2016519107A5 (enExample) | ||
| JP2016041733A5 (enExample) | ||
| HRP20210200T1 (hr) | Kombinirana antitumorska imunoterapija | |
| JP2016536286A5 (enExample) | ||
| JP2021501145A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2017530983A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| CN110678452A (zh) | 亚精胺及其衍生物的应用 | |
| JP2014523398A5 (enExample) | ||
| JP2018521064A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| JP2018062523A5 (enExample) | ||
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. |